These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 29851442

  • 21. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG, Yoon D, Park S, Han SJ, Kim DJ, Lee KW, Park RW, Kim HJ.
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [Abstract] [Full Text] [Related]

  • 22. Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans.
    Klebanoff MJ, Li P, Lin JK, Doshi JA.
    JAMA; 2024 Jul 02; 332(1):74-76. PubMed ID: 38842823
    [Abstract] [Full Text] [Related]

  • 23. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
    Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK.
    Diabetes Care; 2018 Jan 02; 41(1):69-78. PubMed ID: 29109299
    [Abstract] [Full Text] [Related]

  • 24. Proximal Predictors of Long-Term Discontinuance with Noninsulin Antihyperglycemic Agents.
    Stuart BC, Shen X, Quinn CC, Brandt N, Roberto P, Loh FE, Hendrick F, Kim C, Huang X, Rajpathak S.
    J Manag Care Spec Pharm; 2016 Sep 02; 22(9):1019-27. PubMed ID: 27574743
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD, Gershman JA.
    Adv Ther; 2013 Apr 02; 30(4):337-53. PubMed ID: 23605247
    [Abstract] [Full Text] [Related]

  • 26. Medicare Part D Plans Greatly Increased Utilization Restrictions On Prescription Drugs, 2011-20.
    Joyce G, Blaylock B, Chen J, Van Nuys K.
    Health Aff (Millwood); 2024 Mar 02; 43(3):391-397. PubMed ID: 38437610
    [Abstract] [Full Text] [Related]

  • 27. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA, Krumme AA, Avorn J, Brennan T, Matlin OS, Spettell CM, Pezalla EJ, Brill G, Shrank WH, Choudhry NK.
    JAMA Intern Med; 2014 Dec 02; 174(12):1955-62. PubMed ID: 25347323
    [Abstract] [Full Text] [Related]

  • 28. Use of antidiabetic drugs in the U.S., 2003-2012.
    Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK.
    Diabetes Care; 2014 Dec 02; 37(5):1367-74. PubMed ID: 24623020
    [Abstract] [Full Text] [Related]

  • 29. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM, Mogensen UM, Andersson C, Vaag A, Torp-Pedersen C.
    Diabetes Obes Metab; 2014 Mar 02; 16(3):231-6. PubMed ID: 24020750
    [Abstract] [Full Text] [Related]

  • 30. Estimating Medicare Part D's impact on medication access among dually eligible beneficiaries with mental disorders.
    Donohue JM, Frank RG.
    Psychiatr Serv; 2007 Oct 02; 58(10):1285-91. PubMed ID: 17914004
    [Abstract] [Full Text] [Related]

  • 31. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
    Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW.
    Diabetes Res Clin Pract; 2017 Jan 02; 123():199-208. PubMed ID: 28056431
    [Abstract] [Full Text] [Related]

  • 32. Description of anti-diabetic drug utilization pre- and post-formulary restriction of sitagliptin: findings from a national health plan.
    Huang X, Liu Z, Shankar RR, Rajpathak S.
    Curr Med Res Opin; 2015 Aug 02; 31(8):1495-500. PubMed ID: 26073703
    [Abstract] [Full Text] [Related]

  • 33. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH, Charbonnel B, Moses RG, Kalra S.
    Curr Med Res Opin; 2015 Aug 02; 31(10):1919-31. PubMed ID: 26361231
    [Abstract] [Full Text] [Related]

  • 34. Coverage for hepatitis C drugs in Medicare Part D.
    Jung JK, Feldman R, Cheong C, Du P, Leslie D.
    Am J Manag Care; 2016 May 02; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
    [Abstract] [Full Text] [Related]

  • 35. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, Ragghianti B, Monami F, Marchionni N, Mannucci E.
    Adv Ther; 2012 Sep 02; 29(9):736-46. PubMed ID: 22923161
    [Abstract] [Full Text] [Related]

  • 36. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW, Baggesen LM, Søgaard M, Pedersen L, Nørrelund H, Buhl ES, Haase CL, Johnsen SP.
    Diabetologia; 2015 Oct 02; 58(10):2247-53. PubMed ID: 26277380
    [Abstract] [Full Text] [Related]

  • 37. The Effects of a Sitagliptin Formulary Restriction Program on Diabetes Medication Use.
    Tang Y, Huang X, Liu J, Shankar RR, Ganz ML, Rajpathak S.
    Am Health Drug Benefits; 2017 Dec 02; 10(9):456-462. PubMed ID: 29403571
    [Abstract] [Full Text] [Related]

  • 38. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL, Degeeter M, Nuzum DS, Tzefos M.
    Ann Pharmacother; 2013 Apr 02; 47(4):490-505. PubMed ID: 23548652
    [Abstract] [Full Text] [Related]

  • 39. The relationship between the low-income subsidy and cost-related nonadherence to drug therapies in Medicare Part D.
    Wei II, Lloyd JT, Shrank WH.
    J Am Geriatr Soc; 2013 Aug 02; 61(8):1315-23. PubMed ID: 23889465
    [Abstract] [Full Text] [Related]

  • 40. Myopic and Forward Looking Behavior in Branded Oral Anti-Diabetic Medication Consumption: An Example from Medicare Part D.
    Sacks NC, Burgess JF, Cabral HJ, Pizer SD.
    Health Econ; 2017 Jun 02; 26(6):753-764. PubMed ID: 27150938
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.